Safety And Efficacy Of Dexmedetomidine Sedation In Intubated Mechanically Ventilated Infants With Respiratory Failure

• Status: Completed
• Trial end date: 2018-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Dexmedetomidine is a highly selective α2-agonist with hypnotic, analgesic, and anxiolytic properties. Despite off-label administration, dexmedetomidine has found a niche in critically ill mechanically ventilated neonates and infants because of its minimal effects on respiratory function at sedative doses, facilitating early extubation and fast-track postoperative care.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assiut University
• Treatments: Dexmedetomidine

Criteria

Inclusion Criteria:

• Infants (1-12 months).

• Respiratory failure/

• Requiring PICU admission and mechanical ventilation up to 72h.

Exclusion Criteria:

• Significant renal, hepatic, endocrine or metabolic disease.

• 2nd or 3rd degree heart block.

• hypotension or bradycardia (defined as any value outside the normal range from the patient's age).